Business · 21/03/2011Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for VPRIV Patent Extension
Summary
The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for VPRIV, a human drug product, as required by law, following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Health and Human ServicesOpen original release →